Targeting Tumorigenesis: Development and Use of mTOR Inhibitors in Cancer Therapy

Journal of Hematology and Oncology - United Kingdom
doi 10.1186/1756-8722-2-45
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer Development and Progression: Insight to Therapy

Clinical Cancer Drugs
Cancer ResearchToxicologyOncologyPharmaceuticsPharmacology
2016English

mTOR Co-Targeting Strategies for Head and Neck Cancer Therapy

Cancer and Metastasis Reviews
Cancer ResearchOncology
2017English

Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

Apoptosis in Tumorigenesis and Cancer Therapy

Frontiers in Bioscience - Landmark
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
1997English

mTOR Signaling in Tumorigenesis

Biochimica et Biophysica Acta - Reviews on Cancer
Cancer ResearchOncologyGenetics
2014English

Differential Requirement of mTOR in Postmitotic Tissues and Tumorigenesis

Science Signaling
BiochemistryCell BiologyMolecular Biology
2009English

Use of Nanotechnology to Develop Multi-Drug Inhibitors for Cancer Therapy

Journal of Nanomedicine & Nanotechnology
2013English

Proteasome Inhibitors in Cancer Therapy

2004English

mTOR Inhibitors in Cancer: What Can We Learn From Exceptional Responses?

EBioMedicine
BiochemistryMedicineGeneticsMolecular Biology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy